Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Gets CE Mark for Cancer Genomic Profiling Test

NEW YORK — Genetron Health said on Thursday that it has received CE marking for its Onco PanScan genomic profiling test for cancer.

The test uses next-generation sequencing and hybridization capture to detect cancer-linked mutations and variants covering more than 800 genes in order to guide patient treatment and provide cancer risk assessment screening. The gene list includes those recommended by the World Health Organization, National Comprehensive Cancer Network, and European Society for Medical Oncology, the company said.

"In China, Onco PanScan is a key [laboratory-developed test] for us, and we are preparing to start our IVD registrational trial shortly," Sizhen Wang, cofounder and CEO of Genetron Health said in a statement. "Genetron continues to grow all our business lines spanning early screening to diagnosis and monitoring." 

In July, Beijing-based Genetron received the CE mark for its eight-gene lung cancer sequencing assay.


The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.